Adequan Canine

Adequan Canine

Adequan Canine Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Not for use in humans.  Keep this and all medications out of reach of children.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

History

There is currently no drug history available for this drug.

Other Information

The active ingredient in Adequan® Canine is polysulfated glycosaminoglycan (PSGAG). Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan prepared by extracting glycosaminoglycans (GAGs) from bovine tracheal cartilage. GAGs are polysaccharides composed of repeating disaccharide units. The GAG present in PSGAG is principally chondroitin sulfate containing 3 to 4 sulfate esters per disaccharide unit. The molecular weight for PSGAG used in the manufacture of Adequan® is 3,000 to 15,000 daltons.

Each mL of Adequan® Canine contains 100 mg of PSGAG, 0.9% v/v benzyl alcohol as a preservative, and water for injection q.s. to 1 mL. Sodium hydroxide and/or hydrochloric acid added when necessary to adjust pH.

Adequan Canine Manufacturers


  • Novartis Animal Health Us, Inc.
    Adequan Canine (Polysulfated Glycosaminoglycan) Injection, Solution [Novartis Animal Health Us, Inc.]

Login To Your Free Account